Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease

Annals of Neurology

Volumn 52, Issue 2, 2002, Pages 253-256

  Dodel, Richard ^a   Hampel, Harald ^b   Depboylu, Candan ^a   Lin, Suizhen ^c   Gao, Feng ^c   Schock, Sabine ^a   Jäckel, Steffi ^a   Wei, Xing ^c   Buerger, Katharina ^b   Höft, Christine ^a   Hemmer, Bernhard ^a   Möller, Hans Jürgen ^b   Farlow, Martin ^c   Oertel, Wolfgang H ^a   Sommer, Norbert ^a   Du, Yansheng ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY DETECTION; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; MALE; NEUROLOGIC DISEASE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN MODIFICATION; PROTEIN PURIFICATION; REFERENCE VALUE;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODIES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PEPTIDE FRAGMENTS;

EID: 0036327185     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10253     Document Type: Article

References (20)

1. Translating cell biology into therapeutic advances in Alzheimer's disease
2. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier
3. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer
4. Brain drug delivery, drug metabolism, and multidrug resistance at the choroid plexus
5. Biology of A beta amyloid in Alzheimer's disease
6. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition
7. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
8. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
9. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
10. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
11. Reduced CSF levels of amyloid beta-peptide antibody in Alzheimer's disease
12. Statistical methods in medical research
13. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
14. Peripheral anti-A beta antibody alters central nervous system and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease
15. Cerebrospinal fluid analysis: Disease-related data patterns and evaluation programs
16. Human antibodies reactive with beta-amyloid protein in Alzheimer's disease
17. IVIG in neurology-evidence and recommendations
18. Amyloid deposition as the central event in the aetiology of Alzheimer's disease
19. Clearance of amyloid beta-peptide from brain: Transport or metabolism?
20. In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood brain barrier and affects its permeability